Background: Thyroid hormone (TH) disorders increased the risk of metabolic dysfunction-associated fatty liver disease (MAFLD).
Aim: To assess whether the association between TH and MAFLD is mediated via metabolic dysfunctions and varies among MAFLD subtypes (diabetes-MAFLD, overweight/obesity-MAFLD, metabolic disorders-MAFLD).
Methods: A total of 18,427 participants (661 diabetes-MAFLD, 3,600 overweight/obesity-MAFLD, 691 metabolic disorder-MAFLD cases, 13,475 non-MAFLD controls) from a Chinese hospital were enrolled. Hepatic ultrasound measurements and thyroid function were assessed.
Results: Overweight/obesity mediated the associations of MAFLD with triiodothyronine (T3), free triiodothyronine (FT3), free thyroxine (FT4), and the mediator accounted for 46.43%, 39.69%, and 42.68%, respectively. Metabolic disorder mediated the association of MAFLD with T3, FT3, FT4, thyroid stimulating hormone (TSH), and the mediator accounted for 36.57%, 23.19%, 34,65%, and 60.92%, respectively. Diabetes did not complementary mediate any association between TH and MAFLD. Elevated T3, FT3, TSH and decreased FT4 increased the risk of overweight/obesity-MAFLD, and the odds ratios were 1.59, 1.72, 1.18, and 0.60, respectively (Q4 vs.Q1, false discovery rate (FDR)<0.05). Elevated T3, FT3, and decreased FT4 increased the risk of metabolic disorder-MAFLD, and the odds ratios were 1.45, 1.33, and 0.52, respectively (Q4 vs.Q1, FDR<0.05). No significant association between TH and diabetes-MAFLD was detected.
Conclusion: The association between TH and MAFLD is mediated by overweight/obesity and metabolic disorders and varies among MAFLD subtypes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2022.11.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease: review.
EXCLI J
February 2025
Molecular Hepatology Section, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Non-alcoholic Fatty Liver Disease (NAFLD) - whose terminology was recently replaced by metabolic liver disease (MAFLD) - is an accumulation of triglycerides in the liver of >5 % of its weight. Epidemiological studies indicated an association between NAFLD and reduced physical activity. In addition, exercise has been shown to improve NAFLD independently of weight loss.
View Article and Find Full Text PDFExpression profile and N6-methyadenosine modification of circular RNA analysis in MAFLD.
BMC Gastroenterol
March 2025
Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650101, China.
Background: To analyze the expression patterns of circRNAs in metabolic associated fatty liver disease (MAFLD) and the regulation of mA methylation on those circRNAs.
Methods: The expression profile of CircRNA in MAFLD and normal control liver tissues was analyzed by microarray. Predict the potential mA sites of the differentially expression circRNAs (DECs) via the SRAMP website.
SR-A3 suppresses AKT activation to protect against MAFLD by inhibiting XIAP-mediated PTEN degradation.
Nat Commun
March 2025
Institute of Cardiovascular Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, School of Basic Medical Sciences, Peking University, Beijing, China.
Scavenger receptor class A member 3 (SR-A3) is implicated in metabolic diseases; however, the relationship between SR-A3 and metabolic dysfunction-associated fatty liver disease (MAFLD) has not been documented. Here, we show that hepatic SR-A3 expression is significantly reduced in human and animal models in the context of MAFLD. Genetic inhibition of SR-A3 in hamsters elicits hyperlipidemia, hyperglycemia, insulin resistance, and hepatic steatosis under chow-diet condition, yet escalates in diet-induced MAFLD.
View Article and Find Full Text PDFMulti-omics reveal the effects and regulatory mechanism of dietary echinocystic acid supplementation on abdominal fat and liver steatosis in broiler chickens.
Poult Sci
March 2025
College of Animal Science and Technology, Guangxi University, Nanning, 530004, China; Guangxi Key Laboratory of Eye Health, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, China. Electronic address:
The accumulation of abdominal fat and the metabolic dysfunction-associated fatty liver disease (MAFLD) are prevalent problems in the poultry industry, and seriously compromise broiler health and reduce economic benefits. Echinocystic acid (EA), a natural product with anti-inflammatory and antioxidant effects, has been demonstrated to reduce abdominal fat deposition and improve intestinal inflammation in mice. However, it has not been reported in poultry research.
View Article and Find Full Text PDFUnlocking the potential of THR-β agonist therapies: resmetirom's chemistry, biology, and patent insights.
Naunyn Schmiedebergs Arch Pharmacol
March 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's, NMIMS, Deemed to Be University, Vile Parle West, Mumbai, Maharashtra, 400056, India.
Non-alcoholic steatohepatitis (NASH) is a severe manifestation of non-alcoholic fatty liver disease (NAFLD), which is characterized by hepatic steatosis, inflammation, and hepatocyte destruction. Newly adopted nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), allows to signify the importance of metabolic dysfunction. For which the current treatment options are limited and often associated with adverse effects, creating a need for targeted therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!